Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections

Daniel A. Sweeney*, Bonifride Tuyishimire, Neera Ahuja, John H. Beigel, Tatiana Beresnev, Valeria D. Cantos, Jose G. Castro, Stuart H. Cohen, Kaitlyn Cross, Lori E. Dodd, Nathan Erdmann, Monica Fung, Varduhi Ghazaryan, Sarah L. George, Kevin A. Grimes, Noreen A. Hynes, Kathleen G. Julian, Sheetal Kandiah, Hannah Jang Kim, Corri B. LevineDavid A. Lindholm, David C. Lye, Ryan C. Maves, Myoung Don Oh, Catharine Paules, Rekha R. Rapaka, Willam R. Short, Kay M. Tomashek, Cameron R. Wolfe, Andre C. Kalil*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.

Original languageEnglish
Article numberofad205
JournalOpen Forum Infectious Diseases
Volume10
Issue number5
DOIs
StatePublished - 1 May 2023
Externally publishedYes

Keywords

  • COVID-19
  • baricitinib
  • secondary infections

Fingerprint

Dive into the research topics of 'Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections'. Together they form a unique fingerprint.

Cite this